共 18 条
[1]
Teng M.(2003)Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy N Engl J Med 349 446-56
[2]
Wolf M.(2006)Health-economic comparison of paricalcitol, calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis Clin Drug Invest 26 629-38
[3]
Lowrie E.(2004)Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate Osteoporos Int 15 301-10
[4]
Rosery H.(2003)K/DOQI clinical practice guidelines: bone metabolism and disease in chronic kidney disease Am J Kidney Dis 42 S1-S201
[5]
Bergemann R.(2002)Pharmacokinetics of 1,25(OH)2D3 and 1α(OH)D3 in normal and uraemic men Nephrol Dial Transplant 17 829-42
[6]
Marx S.E.(2004)Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings Nephrol Dial Transplant 19 1174-81
[7]
Richy F.(2006)for the Medical Directors of Dialysis Clinic Inc. Mortality risk among hemodialysis patients receiving different vitamin D analogs Kidney Int 70 1858-65
[8]
Ethgen O.(undefined)undefined undefined undefined undefined-undefined
[9]
Bruyere O.(undefined)undefined undefined undefined undefined-undefined
[10]
Brandi L.(undefined)undefined undefined undefined undefined-undefined